V

Ventyx Biosciences
D

VTYX

1.61000
USD
-0.06
(-3.59%)
مغلق
حجم التداول
15,779
الربح لكل سهم
-3
العائد الربحي
-
P/E
-1
حجم السوق
113,844,174
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأخبار
المقالات

العنوان: Ventyx Biosciences

القطاع: Healthcare
الصناعة: Biotechnology
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.